临床研究
ENGLISH ABSTRACT
复方樟柳碱注射液治疗前部缺血性视神经病变有效性和安全性的Meta分析
廖良
王妍
韦企平
作者及单位信息
·
DOI: 10.3760/cma.j.cn115989-20211026-00586
Efficacy and safety of compound anisodine injection for anterior ischemic optic neuropathy: a meta-analysis
Liao Liang
Wang Yan
Wei Qiping
Authors Info & Affiliations
Liao Liang
Department of Ophthalmology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China
Wang Yan
The Second Clinical School of Beijing University of Chinese Medicine, Beijing 100078, China
Wei Qiping
Department of Ophthalmology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China
·
DOI: 10.3760/cma.j.cn115989-20211026-00586
603
104
0
0
4
0
PDF下载
APP内阅读
摘要

目的系统评价复方樟柳碱注射液(CA)对前部缺血性视神经病变(AION)的有效性和安全性。

方法检索1978年1月至2021年6月PubMed、Cochrane图书馆、Web of Science、中国知网、万方数据库、中文科技期刊全文数据库和中国生物医学文献光盘数据库中CA参与治疗AION的随机对照试验(RCT),由2名研究者独立筛选文献、提取资料并评价纳入研究的偏倚风险后,采用RevMan 5.3进行Meta分析。

结果符合纳入标准的RCT文献13篇,共1 636眼,治疗组829眼,未经CA治疗的对照组807眼。治疗组治疗总有效率较对照组高[比值比( OR)=3.25,95%置信区间( CI):2.47~4.28, P<0.01],治疗组最佳矫正视力优于对照组[均数差(MD)=0.14,95% CI:0.11~0.17, P<0.01],剔除异质性大的文献后治疗组最佳矫正视力仍优于对照组(MD=0.14,95% CI:0.12~0.16, P<0.01)。治疗组视野平均缺损小于对照组(MD=-2.58,95% CI:-3.98~-1.19, P<0.01),视野平均光敏感度高于对照组(MD=3.49,95% CI:3.07~3.91, P<0.01)。

结论CA治疗AION的疗效优于未使用CA的对照组,其疗效主要是提高视力和视野平均敏感度、降低视野平均缺损。

缺血性视神经病变;复方樟柳碱;治疗效果;系统评价;Meta分析
ABSTRACT

ObjectiveTo evaluate the efficacy and safety of compound anisodine (CA) injection for anterior ischemic optic neuropathy (AION).

MethodsStudies, which were randomized controlled trials (RCT) of CA with routine treatment for AION from PubMed, The Cochrane Library, Web of Science, CNKI, Wanfang database, Chinese science and technology journals full-text database and CD-ROM database of Chinese Biology Medical disc published from January 1978 to June 2021 were searched.Included studies were screened by two researchers independently based on inclusion and exclusion criteria.After data collection and quality assessment, a meta-analysis of included studies was performed with Revman 5.3 software.

ResultsThirteen RCT were included, involving 1 636 eyes, with 829 eyes in treatment group and 807 eyes in control group without CA treatment.It was found that the total effective rate of treatment group was higher than that of control group ( OR=3.25, 95% CI: 2.47-4.28, P<0.01), and the best corrected visual acuity of AION patients after CA treatment was significantly better than that of control group when articles with high heterogeneity were excluded (MD=0.14, 95% CI: 0.11-0.17, P<0.01) or not (MD=0.14, 95% CI: 0.12-0.16, P<0.01).The mean defect of visual field was significantly smaller and the mean sensitivity of visual field was higher in treatment group than control group (MD=-2.58, 95% CI: -3.98--1.19, P<0.01; MD=3.49, 95% CI: 3.07-3.91, P<0.01).

ConclusionsCA shows good efficacy in the treatment of AION.It can improve visual acuity and mean sensitivity of visual field, decrease mean defect of visual field.

Optic neuropathy, ischemic;Compound anisodine;Treatment outcome;Systematic review;Meta-analysis
Wei Qiping, Email: mocdef.3ab6136753112631
引用本文

廖良,王妍,韦企平. 复方樟柳碱注射液治疗前部缺血性视神经病变有效性和安全性的Meta分析[J]. 中华实验眼科杂志,2022,40(07):645-650.

DOI:10.3760/cma.j.cn115989-20211026-00586

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价
前部缺血性视神经病变(anterior ischemic optic neuropathy,AION)是视神经营养血管循环障碍所致的常见眼病,多见于老年人。AION临床特点为无痛性的视力突然下降,患眼视盘水肿,视野多出现与生理盲点相连的扇形或神经纤维束样缺损。AION多由供应视盘的睫状后短动脉短暂的无灌注或低灌注所致 [ 1 ],治疗时应避免使用强效全身扩张血管药物,以免进一步降低睫状后短动脉的灌注压。复方樟柳碱注射液(compound anisodine,CA)主要通过激活微血管自律运动来增加局部供血供氧,而非扩张血管,故正常剂量CA并不会引起供血动脉灌注压降低及全身血压下降 [ 2 ]。CA在临床应用已达二十余年,国内已形成CA临床应用专家共识,为其治疗缺血性眼部病变提供规范性指导 [ 3 ]。近年来大量文献报道CA治疗缺血性视神经病变均取得不同程度疗效,但尚缺乏最新的循证医学评价。本研究拟对CA治疗AION的有效性和安全性进行系统评价,并按PRISMA规范进行报告 [ 4 ],以期为CA的临床合理用药提供依据。
试读结束,您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
Hayreh SS . Ischemic optic neuropathy[J]. Prog Retin Eye Res 200928(1)∶34-62. DOI: 10.1016/j.preteyeres.2008.11.002 .
返回引文位置Google Scholar
百度学术
万方数据
[2]
于强吴景天董东生复方樟柳碱治疗原发性和继发性缺血性视神经视网膜脉络膜病变[J]. 中华眼底病杂志 200016(2)∶71-74. DOI: 10.3760/j.issn:1005-1015.2000.02.001 .
返回引文位置Google Scholar
百度学术
万方数据
Yu Q , Wu JT , Dong DS et al. Clinical observation of the effects of compound anisodine on treatment of primary and secondary ischemic optic neuropathy and choroidoretinopathy[J]. Chin J Ocul Fundus Dis 200016(2)∶71-74. DOI: 10.3760/j.issn:1005-1015.2000.02.001 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[3]
中华医学会眼科学分会神经眼科学组中国医药教育协会眼科专业委员会复方樟柳碱临床应用专家共识专家组复方樟柳碱注射液在常见缺血性眼病中应用专家共识(2020版)[J]. 中华实验眼科杂志 202038(7)∶553-561. DOI: 10.3760/cma.j.cn115989-20200416-00266 .
返回引文位置Google Scholar
百度学术
万方数据
Experts Consensus Group of Compound Anisodine Injection Application,Neuroophthalmology Group Society of Ophthalmology of Chinese Medical Association,Ophthalmology Committee of China Medical Education Association. Chinese experts consensus on compound anisodine injection in the ischemic ophthalmopathy clinical practice (2020)[J]. Chin J Exp Ophthalmol 202038(7)∶553-561. DOI: 10.3760/cma.j.cn115989-20200416-00266 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[4]
Moher D , Liberati A , Tetzlaff J et al. Preferred reporting items for systematic reviews and meta-analyses:the PRISMA statement[J/OL]. BMJ 2009339b2535[2021-09-12]. https://www.bmj.com/content/339/bmj.b2535. DOI: 10.1136/bmj.b2535 .
返回引文位置Google Scholar
百度学术
万方数据
[5]
中华医学会眼科学分会神经眼科学组我国非动脉炎性前部缺血性视神经病变诊断和治疗专家共识(2015年)[J]. 中华眼科杂志 201551(5)∶323-326. DOI: 10.3760/cma.j.issn.0412-4081.2015.05.002 .
返回引文位置Google Scholar
百度学术
万方数据
[6]
何军复方樟柳碱对糖尿病缺血性视神经病变疗效分析及对患者视力的影响[J]. 临床和实验医学杂志 201615(8)∶768-770,771. DOI: 10.3969/j.issn.1671-4695.2016.08.017 .
返回引文位置Google Scholar
百度学术
万方数据
He J Study on the efficacy of compound anisodine on diabetic ischemic optic neuropathy and vision in patients with diabetes mellitus[J]. J Clin Exp Med 201615(8)∶768-770,771. DOI: 10.3969/j.issn.1671-4695.2016.08.017 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[7]
杭丽复方樟柳碱联合针灸治疗缺血性视神经病变的疗效观察[J]. 国际眼科杂志 20088(10)∶2141-2142.
返回引文位置Google Scholar
百度学术
万方数据
Hang L Effect of the compound anisodine injection combined acupuncture therapy on ischemic optic neuropathy[J]. Int Eye Sci 20088(10)∶2141-2142.
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[8]
黄翠李进复方樟柳碱颞浅动脉旁注射辅助治疗对糖尿病合并早期前部缺血性视神经病变的疗效观察[J]. 糖尿病新世界 201922(14)∶177-178. DOI: 10.16658/j.cnki.1672-4062.2019.14.177 .
返回引文位置Google Scholar
百度学术
万方数据
[9]
李志伟复方樟柳碱治疗缺血性视神经病变的临床观察[J]. 养生保健指南 20204116.
返回引文位置Google Scholar
百度学术
万方数据
[10]
崔庆霞复方樟柳碱治疗糖尿病性缺血性视神经病变[J]. 光明中医 201631(12)∶1689-1691. DOI: 10.3969/j.issn.1003-8914.2016.12.006 .
返回引文位置Google Scholar
百度学术
万方数据
Cui QX . Compound anisodine in the treatment of diabetic ischemic optic neuropathy[J]. Guangming J Chin Med 201631(12)∶1689-1691. DOI: 10.3969/j.issn.1003-8914.2016.12.006 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[11]
王永斌复方樟柳碱注射液联合银杏达莫注射液治疗前部缺血性视神经病变的疗效探讨[J]. 湖南师范大学学报:医学版 201411(3)∶61-63.
返回引文位置Google Scholar
百度学术
万方数据
Wang YB . Curative effect investigation of Yinxingdamo injection compared with compound anisodine injection in the treatment of ischemic optic neuropathy[J]. J Hunan Normal Univ (Medical Science) 201411(3)∶61-63.
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[12]
秦常军吴怡复方樟柳碱注射液治疗前部缺血性视神经病变的疗效观察[J]. 吉林医学 201435(7)∶1363-1364.
返回引文位置Google Scholar
百度学术
万方数据
Qin CJ , Wu Y Observation of the effects of compound anisodine on treatment of ischemic optic nerve diseases[J]. Jilin Med J 201435(7)∶1363-1364.
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[13]
郑茜复方樟柳碱注射液治疗前部缺血性视神经病变的疗效观察[J]. 中国现代药物应用 201610(12)∶143-144. DOI: 10.14164/j.cnki.cn11-5581/r.2016.12.107 .
返回引文位置Google Scholar
百度学术
万方数据
[14]
邝国平武正清谢丽莲复方樟柳碱注射液治疗缺血性视神经病变的疗效观察[J]. 医学信息 201326(21)∶76-77.
返回引文位置Google Scholar
百度学术
万方数据
Kuang GP , Wu ZQ , Xie LL et al. Effect of compound anisondine on ischemic optic neuropathy[J]. Med Inform 201326(21)∶76-77.
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[15]
陆新安阮丹徐春柳复方樟柳碱注射液治疗缺血性视神经病变的疗效观察[J]. 中国生化药物杂志 201637(2)∶128-129,132.
返回引文位置Google Scholar
百度学术
万方数据
Lu XA , Ruan D , Xu CL et al. Effect of compound anisodine injection on ischemic optic neuropathy[J]. Chin J Biochem Pharm 201637(2)∶128-129,132.
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[16]
陈迪清复方樟柳碱注射液治疗缺血性视神经病变的临床效果分析[J]. 特别健康 2021398.
返回引文位置Google Scholar
百度学术
万方数据
[17]
王丽丽甲强龙联合复方樟柳碱治疗前部缺血性视神经病变的疗效观察[J]. 环球中医药 20158(S1)∶225.
返回引文位置Google Scholar
百度学术
万方数据
[18]
王朝晖颞浅动脉旁皮下注射复方樟柳碱治疗缺血性视神经病变的临床效果观察[J]. 河南医学研究 201524(3)∶102-103. DOI: 10.3969/j.issn.1004-437X.2015.03.055 .
返回引文位置Google Scholar
百度学术
万方数据
[19]
张颖张慧芝张英杰复方樟柳碱注射液联合维生素B12注射液局部注射治疗原发性和继发性缺血性视神经病变的疗效观察[J]. 中国医院用药评价与分析 201717(1)∶25-27,31. DOI: 10.14009/j.issn.1672-2124.2017.01.008 .
返回引文位置Google Scholar
百度学术
万方数据
Zhang Y , Zhang HZ , Zhang YJ et al. Observation on efficacy of compound anisodine injections combined with vitamin B12 injections in treatment of primary and secondary ischemic optic neuropathy[J]. Eval Anal Drug-Use Hosp China 201717(1)∶25-27,31. DOI: 10.14009/j.issn.1672-2124.2017.01.008 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[20]
Wu F , Wang J , Sun J et al. Procaine stimulates aquaporin-5 expression in human salivary gland ductal cells via the suppression of DNA methyltransferase-1[J]. Mol Med Rep 201817(6)∶7996-8002. DOI: 10.3892/mmr.2018.8821 .
返回引文位置Google Scholar
百度学术
万方数据
[21]
胡白凤杨凤玉简述普鲁卡因的内科临床应用[J]. 医学信息 201124(3)∶267-268.
返回引文位置Google Scholar
百度学术
万方数据
[22]
陈晓燕浅谈普鲁卡因在临床上的用途[J]. 当代医药论丛 201412(15)∶155-156.
返回引文位置Google Scholar
百度学术
万方数据
[23]
宋琛缺血性眼病治疗新概念[M]. 2版北京人民军医出版社 200997-105.
[24]
周贤刚钟渠许明德复方樟柳碱注射液治疗缺血性视神经病变的系统评价[J]. 临床眼科杂志 200614(3)∶229-234. DOI: 10.3969/j.issn.1006-8422.2006.03.015 .
返回引文位置Google Scholar
百度学术
万方数据
Zhou XG , Zhong Q , Xu MD . Compound anisodine injection for ischemic optic neuropathy:a systematic review[J]. J Clin Ophthalmol 200614(3)∶229-234. DOI: 10.3969/j.issn.1006-8422.2006.03.015 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[25]
吴星白永怿魏世辉复方樟柳碱治疗缺血性眼病的荟萃分析[J]. 中国中医眼科杂志 201222(3)∶183-187.
返回引文位置Google Scholar
百度学术
万方数据
Wu X , Bai YY , Wei SH . Compound anisodine is effective in the treatment of ocular ischemia:a meta-analysis[J]. Chin J Chin Ophthalmol 201222(3)∶183-187.
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
备注信息
A
韦企平,Email: mocdef.3ab6136753112631
B

廖良:文献检索与筛选、偏倚评价、数据收集、文章撰写;王妍:文献检索与筛选、纳入文献偏倚评价、数据分析;韦企平:酝酿与设计试验、文章知识性内容的批评性审阅

C
所有作者均声明不存在利益冲突
评论 (0条)
注册
登录
时间排序
暂无评论,发表第一条评论抢沙发
MedAI助手(体验版)
文档即答
智问智答
机器翻译
回答内容由人工智能生成,我社无法保证其准确性和完整性,该生成内容不代表我们的态度或观点,仅供参考。
生成快照
文献快照

你好,我可以帮助您更好的了解本文,请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持:

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号